Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia

International Journal of Tuberculosis and Lung Disease

Volumn 6, Issue 6, 2002, Pages 497-502

  Van Crevel, Reinout ^a   Alisjahbana, B ^a   De Lange, W C M ^a   Borst, F ^a   Danusantoso, H ^a   Van der Meer, J W M ^a   Burger, D ^a   Nelwan, R H H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biological bioavailability; Clinical pharmacology; Indonesia; Rifampicin; Tuberculosis treatment

Indexed keywords

RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG MANUFACTURE; FEMALE; HUMAN; INDONESIA; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SPUTUM ANALYSIS; TREATMENT FAILURE; BIOAVAILABILITY; CHEMISTRY; MIDDLE AGED;

ADOLESCENT; ADULT; ANTIBIOTICS, ANTITUBERCULAR; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; FEMALE; HUMANS; INDONESIA; MALE; MIDDLE AGED; RIFAMPIN; TUBERCULOSIS, PULMONARY;

EID: 0036015669     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/09640569513002     Document Type: Article

References (33)

1. Role of individual drugs in the chemotherapy of tuberculosis
2. Consensus statement. Global burden of tuberculosis: Estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project
3. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials
4. Substandard tuberculosis drugs on the global market and their simple detection
5. Pharmacopoeial quality of drugs supplied by Nigerian pharmacies
6. Drug malabsorption and resistant tuberculosis in HIV-infected patients
7. US Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis
8. Poor micronutrient status of active pulmonary tuberculosis patients in Indonesia
9. Standardized tuberculosis treatment outcome monitoring in Europe. Recommendations of a Working Group of the World Health Organization (WHO) and the European Region of the International Union Against Tuberculosis and Lung Disease (IUATLD) for uniform reporting by cohort analysis of treatment outcome in tuberculosis patients
10. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids
11. Automated high-performance liquid chromatographic method for the determination of rifampicin in plasma
12. Using therapeutic drug monitoring to dose the antimycobacterial drugs
13. Low rifapentine, rifampin and isoniazid plasma levels are not predicted by clinical and demographic variables
14. Pharmacokinetic factors in the modern drug treatment of tuberculosis
15. Malabsorption of antituberculosis medications by a patient with AIDS
16. Low antituberculosis drug concentrations in patients with AIDS
17. Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection
18. Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients
19. Sex difference in blood levels of some antibiotics
20. India's trade in fake drugs-bringing the counterfeiters to book
21. Bioavailability of rifampicin capsules
22. Drug combinations and the bioavailability of rifampicin
23. Rifampicin bioavailability: A review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption
24. A controlled trial of 6 months chemotherapy in pulmonary tuberculosis. Final report: Results during the 36 months after the end of chemotherapy and beyond
25. Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis
26. Risk factors for rifampin mono-resistant tuberculosis
27. Failure of drug penetration and acquisition of drug resistance in chronic tuberculous empyema
28. Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy
29. The early bactericidal activity of drugs in patients with pulmonary tuberculosis
30. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications